Pregnancy in acromegalic patients is a rare event, but is usually uneventful, with stable GH and IGF-I levels and no tumor enlargement. Medical treatment can usually be withdrawn without problems and although no major adverse event has been reported, the suspension of drug treatments is generally recommended. No case report exists in the literature regarding evolution of a somatotropinoma with invasiveness markers throughout pregnancy. We report a case of an acromegalic patient who was submitted to surgery and treated with octreotide LAR maintaining a stable residual tumor and an IGF-I close to the normal levels. Her tumor presented with a high Ki-67 (11.6%) and a low aryl hydrocarbon receptor-interacting protein (AIP) expression. When she became pregnant, octreotide LAR was withdrawn, and despite remaining asymptomatic during pregnancy, tumor growth occurred with compression of surrounding structures. In conclusion, pregnancy in acromegalic patients has usually a favorable prognosis with no tumor growth. However, in the presence of high Ki-67 labeling index and low AIP expression, tumor enlargement may occur and somatostatin analogue treatment throughout the pregnancy should be considered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1507/endocrj.ej11-0306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pregnancy and acromegaly: clinical outcomes of retrospectively analysed data from the German acromegaly registry.
Reprod Biol Endocrinol
April 2024
Institute of Endocrinology and Diabetes, University of Lübeck, Lübeck, Germany.
Context: Acromegaly is a rare disease caused by excessive growth hormone (GH) secretion, mostly induced by pituitary adenomas. The care of pregnant women with acromegaly is challenging, in part due to existing clinical data being limited and not entirely consistent with regard to potential risks for mother and child.
Objective: To retrospectively examine data on pregnancy and maternal as well as neonatal outcomes in patients with acromegaly.
Safety of pregnancy in acromegaly patients and maternal and infant outcomes after pregnancy: single-center experience from China and review of the literature.
BMC Endocr Disord
May 2023
Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Background: Pregnancy in acromegaly is uncommon and still in debate for fear of tumor progression or potential threat to both mother and fetus's health. Besides, the data for pregnancy complications in uncontrolled acromegaly is limited. Thus, the objective of this study was to summarize pregnancy safety and disease courses after pregnancy in acromegalic patients and review their clinical characteristics based on disease activity in the literature.
View Article and Find Full Text PDFFertility in Acromegaly: A Single-Center Experience of Female Patients During Active Disease and After Disease Remission.
J Clin Endocrinol Metab
July 2023
Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, 80131 Naples, Italy.
Article Synopsis
- The study focuses on how acromegaly affects fertility and gonadal function in women.
- At the onset of the disease, 32% of patients reported menstrual issues, and 36.8% were infertile, with various reproductive health concerns observed through gynecological exams.
- After disease control, menstrual disturbances decreased slightly, and 73.3% of women who wanted to conceive managed to do so, leading to a lower infertility rate of 26.7%.
- Overall, the findings suggest that managing acromegaly can positively influence reproductive health outcomes for affected women.
Approach of Acromegaly during Pregnancy.
Diagnostics (Basel)
November 2022
Department of Endodontics, Faculty of Dental Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Acromegaly-related sub/infertility, tidily related to suboptimal disease control (1/2 of cases), correlates with hyperprolactinemia (1/3 of patients), hypogonadotropic hypogonadism—mostly affecting the pituitary axis in hypopituitarism (10−80%), and negative effects of glucose profile (GP) anomalies (10−70%); thus, pregnancy is an exceptional event. Placental GH (Growth Hormone) increases from weeks 5−15 with a peak at week 37, stimulating liver IGF1 and inhibiting pituitary GH secreted by normal hypophysis, not by somatotropinoma. However, estrogens induce a GH resistance status, protecting the fetus form GH excess; thus a full-term, healthy pregnancy may be possible.
View Article and Find Full Text PDFEffect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function.
J Clin Med
July 2022
Department of Clinical and Molecular Medicine, ENETS Center of Excellence, Sapienza University of Rome, 00185 Rome, Italy.
Article Synopsis
- * This review examines how various NEN treatments, like somatostatin analogues and chemotherapy, impact male and female reproductive systems, although there is insufficient data on these effects.
- * While chemotherapy negatively affects fertility, the influence of somatostatin analogues on fertility is unclear, and there is very little information on how NEN treatments affect sexual function overall.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!